Tungstate reduces blood pressure in experimental animal models of both hypertension and metabolic syndrome, although the underlying mechanisms are not fully understood. Given that the large-conductance voltage-and Ca 2+ -dependent K + (BK) channel is a key element in the control of arterial tone, our aim was to evaluate whether BK channel modulation by tungstate can contribute to its antihypertensive effect.
Introduction
Arterial resistance, which is mainly controlled by the basal tone of the vascular smooth muscle cells (VSMCs), determines the rate of blood flow to tissues. Both circulating factors and those resident at the vessel wall participate in the establishment of this tone, and their malfunction is typically associated with functional and structural alterations in the vessels of patients suffering from essential hypertension. 1 It is therefore important to identify the molecular and genetic elements participating in the control of vascular tone and their possible use as targets with therapeutic potential.
Among the factors controlling vascular tone, voltage-gated ion channels mediating Ca 2+ entry into the VSMCs and their regulatory mechanisms are central to this process. 2 One such key regulatory mechanism involves the large-conductance voltage-and Ca 2+ -activated K + (BK) channel. The BK channel couples local increases in intracellular Ca 2+ to augmented channel activity, membrane hyperpolarization (preventing the activation of L-type Ca 2+ channels), and vascular relaxation. 3 Medications already exist that target different mechanisms involved in blood pressure regulation, 4 although its normalization is not always satisfactory, and none of them targets BK channels. Compared with currently used hypertension treatments, such as Ca 2+ antagonists, BK channel openers are expected to potentiate an existing physiological regulatory system that acts as a negative feedback mechanism to limit membrane depolarization, L-type Ca 2+ channel opening, and the subsequent VSMC contraction. 3 BK channels, formed by a subunit tetramers, are encoded by a single gene, SLO (KCNMA1), and are activated by membrane depolarization and binding of intracellular Ca 2+ and Mg 2+ , the effects of which are additive and involve independent pathways. 5, 6 Accordingly, distinct binding sites for physiological concentrations of Ca 2+ (in the micromolar range) and Mg 2+ (in the millimolar range) have been identified in the pore-forming a channel subunit. 6 -8 Mg 2+ blocks the pore of BK channels in a voltage-dependent manner, 6, 9 but also enhances BK channel activation by stabilizing the open states. This results in a shift of the conductance-voltage (G-V) relationship to a more negative voltage range, an effect that is independent of voltage-sensor movement or Ca 2+ binding to the channel. 6, 10 Channel activation by Mg 2+ requires a divalent cation binding site that consists of amino acid side-chains from both the voltage-sensor domain (VSD; D99 and N172) and the first cytoplasmic regulator of conductance for K + (RCK1) domain (E374 and E399) of the BK a channel subunit. 8 Depending on the tissue, BK a subunits associate with different auxiliary b subunits (b 1 -b 4 ), modifying BK subcellular distribution and gating, thereby contributing to channel diversity and involvement in different physiological processes. 11 The molecular composition of the vascular BK channel includes the regulatory b 1 subunit, whose expression increases channel sensitivity to Ca 2+ , favouring its activation by low Ca 2+ sparks. 12 Moreover, the presence of the b 1 subunit is relevant to smooth muscle contraction induced by vasoactive peptides and the regulation of arterial tone and blood pressure both in animal models of hypertension and in humans. 13 -18 Altogether, this makes the vascular BKab 1 channel an attractive target for the development of new antihypertensive therapies. Tungstate, a compound with antidiabetic 19 and antiobesity properties, 20 has been reported to reduce blood pressure in experimental animal models of both hypertension 21, 22 and metabolic syndrome. 23 The antihypertensive action of tungstate has been associated with inhibition of the increased xanthine oxidase activity in endothelial cells of hypertensive animals. 21 Given the key role of BK channels in arterial tone control and the reported antihypertensive effect of tungstate, we assessed the effect of tungstate on BK channel activity and arterial contractility.
Methods

Cell transfection
HEK 293 cells were transfected using polyethylenimine ExGen 500 (Fermentas Inc., Hanover, MD, USA), following the manufacturer's instructions [seven equivalents of polyethylenimine per 3.3 mg of complementary DNAs expressing the wild-type (WT), D99A or the N172A BK channel human a subunit alone or with one of the four different human b subunits (b 1 -4 ; 1:2 ratio), together with the transfection reporter pEGFPN1].
Electrophysiology
Inside-out ionic currents were recorded in macropatches from EGFPpositive cells, 2 -3 days after transfection. 17 For current-activation studies, membrane macropatches were clamped at 0 mV, pulsed for 150 ms (or 20 ms for expressed BK channels containing the inactivating b 2 regulatory subunit) from -100 to +200 mV in 10 mV steps, and repolarized to -80 mV for 20 ms. Experiments were performed at room temperature (22 -268C). Relative conductance was determined by measuring tail current amplitudes at -80 mV. For each patch, the G-V relationship was fitted with the following Boltzmann equation:
where G is the value of the instantaneous tail current at each test voltage, G max is the maximal obtained tail current, V is the test voltage applied to the membrane, V1 2 act is the voltage for half-maximal current activation, and k act (an index of the minimal number of elementary charges that move through the electric field to gate the channel) is the slope factor of the Boltzmann term. The G -V curves shown in the figures represent averages from a set of patches in the indicated experimental conditions.
2.3 Putative tungstate binding sites at the human pore-forming a subunit of the BK channel
To obtain some insight into structural features of tungstate-protein interactions, we analysed the residue composition in the tungstate binding site of 45 available X-ray structures (see Supplementary material online for a complete list of the protein data bank identifiers (PDB IDs) and Supplementary material online, Table S1 ). These studies supported the role of divalent cations as cofactors for tungstate binding, and they allowed us to suggest putative tungstate binding sites at the human BKa subunit based on an identified aspartate-lysine/lysine-aspartate (DK/KD) motif. Interestingly, the two BKa regions that include the Mg 2+ binding site 8 contain a DK/KD motif within or next to the relevant D99, N172, and E374 residues (Supplementary material online, Figures S1-S3 and Table S2 ). 
Arterial tension measurements
Results
Effect of tungstate on BK channels of different molecular composition
To evaluate whether tungstate modulates BK channel activity, we expressed the human a subunit alone or with one of the four human regulatory b subunits (b 1 -4 ) in HEK 293 cells. Figure 1 (A, C, E, G, and I ) shows representative BK currents, recorded before and Figure 1L ), which is a convenient parameter to study the effect of BK channels modulators because it is directly related to the energy required to open the channel. We found that tungstate produced a significant decrease of the V1 2 act values (by 22 mV) only for b 1 -or b 4 -containing BK channels, favouring their activation. Tungstate did not change the slope factor of the fitted G-V curves (k act ), suggesting no interference with the voltage-sensing process of BK gating ( Figure 1M) .
We also studied whether tungstate-induced activation of BKab 1 channels was modified by increasing [Ca 2+ ] up to values detected near BKab 1 channels during VSMC contraction ( 10 mM). 25 The inhibitory effect of tungstate (1 mM) on BKb 1 current amplitude was significantly smaller (P , 0.05) at 10 mM Ca 2+ (Figure 2A and C ). reduced the current amplitude in a dose-dependent manner at positive voltages ( Figure 3A and G, open bars). Mg 2+ also left shifted the Role of BK channels in tungstate-induced vasodilatation G-V curve of the human BKb 1 channel ( Figure 3B) , thereby reducing the channel V1 2 act , without affecting the curve slope ( Figure 3H and I, open circles). Tungstate (1 mM) produced a similar reduction of BKab 1 current amplitude in the absence or presence of cytosolic Mg 2+ ( Figure 3C , E, and G, filled bars). However, removal of cytosolic Mg 2+ prevented the tungstate-induced decrease of BKab 1 channel V1 2 act ( Figure 3D and H ). In the presence of 5 mM Mg 2+ , tungstate was not able to produce a further V1 2 act reduction beyond the one induced by the divalent cation ( Figure 3F and H ) .
The Mg 2+ requirement for the tungstate effect was further tested on human BKab 1 channels containing mutations in residues of the a subunit VSD that contribute to Mg 2+ co-ordination. The D99A mutation abolishes and the N172A mutation substantially reduces the Mg 2+ -induced activation of mSlo channels. 8 Supplementary material online, Figure S3 shows the position of these mutations and the alignment of human and mouse BK channel VSD linkers containing the mutations. In accordance with previous reports on the mouse BK channel, the introduction of the D99A and N172A mutations slightly modified the V1 2 act for human BKab 1 channels in the absence of divalent cations (Supplementary material online, Figure S4E 4 22 , filled circles) for WT (n ¼ 7, P , 0.0001, Student's paired t-test; data replotted from Figure 1 for direct comparison), D99A mutant (n ¼ 4, P ¼ 0.49, Mann-Whitney U-test) and N172A mutant BKab 1 channels (n ¼ 3,
positive voltages without significant effects on the G-V curves (Supplementary material online, Figure S4 ). This is consistent with the idea that Mg 2+ -induced blockade and activation of BK channels occur via different binding sites. When exposed to 1 mM tungstate, both D99A and N172A human BKab 1 channels presented a reduction in current amplitude similar to that observed for WT channels ( Figure 4A , C, and E), but lost the tungstate-induced channel activation ( Figure 4B , D, and F ). Figure S5 ), an effect consistent with the considerable degree of BK current inhibition produced by this concentration of tungstate, independently of the presence of the b 1 subunit (see Figure 1A , C, and K ). However, lowering the tungstate concentration to 0.1 mM did not significantly affect the basal tension (Supplementary material online, Figure S5 ). Therefore, we evaluated whether 0.1 mM tungstate could yet modulate heterologously expressed BK channels.
In the absence of b 1 , 0.1 mM tungstate produced a small reduction of BK currents ( Figure 5A and E), but was ineffective in left shifting the G-V relationship ( Figure 5B ) or the V1 2 act ( Figure 5F ). In the presence of b 1 , 0.1 mM tungstate did not inhibit BK currents ( Figure 5C) ; moreover, there was a slight increase in the overall current ( Figure 5E ) and a significant left shift in the G-V curve ( Figure 5D ), resulting in a 10 mV decrease of V1 2 act ( Figure 5F ). Thus, 0.1 mM tungstate activates BKab 1 channels without negatively altering BKab 1 current amplitude.
Next, we tested the effect of 0.1 mM tungstate on femoral arterial rings. Exposure of femoral arterial rings to K + depolarizing solutions produced marked and reversible contractile responses in both WT ( Figure 6A ) and b 1 -knockout arteries ( Figure 6B) . Arterial rings were then pre-contracted with endothelin-1 (ET-1; 50 nM), an efficacious -dependent induced activation of BK channels, 0.1 mM tungstate significantly reduced arterial tension after 5 min of application on pre-contracted arterial rings from wild-type mice, a vasodilatory effect that was maximal after 20 min of tungstate exposure ( Figure 6A and C ) . This effect of tungstate was reversed by the addition of the BK channel blocker paxilline ( Figure 6A) , and was not mimicked by the xanthine oxidase inhibitor allopurinol (100 mM; Figure 6C ). No vasodilatory action was observed for tungstate in arterial rings obtained from b 1 -knockout mice ( Figure 6B) . In fact, a vasocontractile response was observed within 15 -20 min of tungstate (0.1 mM) application in the pre-contracted arteries of b 1 -knockout mice ( Figure 6C) , probably owing to its inhibitory effect on BKa current amplitude (see Figure 5A and E).
Discussion
Large-conductance, Ca 2+ -dependent potassium (BK) channels are important for the control of vascular tone. 3 BK channels are activated in vascular smooth muscle by local Ca 2+ transients ('Ca 2+ sparks') caused by the opening of a cluster of ryanodine receptors in the sarcoplasmic reticulum membrane adjacent to the cell membrane. Such activation results in an efflux of K + that is sufficient to hyperpolarize the membrane potential, providing a negative feedback mechanism that limits membrane depolarization and contraction. 27 Accordingly, the blockade of BK channels or ryanodine receptors in arterial smooth muscle causes depolarization, an elevation of arterial wall Ca 2+ concentration, and vasoconstriction. Furthermore, a wide variety of vasodilators exert their actions through activation of BK channels. 28 -30 The presence of the regulatory b 1 subunit (highly expressed in smooth muscle, but not in other tissues 13, 31 ) has been shown to increase the apparent voltage and Ca 2+ sensitivity of the BK channel pore-forming a subunit, 32 making the negative feedback loop more efficient in the regulation of vascular resistance.
13,14 A.I. Fernández-Mariño et al.
Thus, in b 1 -knockout mice Ca 2+ sparks are functionally uncoupled from BK channel activation, leading to membrane potential depolarization, vasoconstriction, elevation of blood pressure, and left ventricular hypertrophy. 13, 14 In commonly used rat models of hypertension, including spontaneously hypertensive rats and rats made hypertensive by chronic infusion of a vasoconstrictor peptide, elevated blood pressure is associated with a down-regulation of the b 1 subunit, but not the a subunit, of the BK channel. 15, 16 Besides, and more interesting in the context of human disease, a gain-of-function BK channel b 1 subunit variant has been reported to protect against moderate to severe diastolic hypertension and 'combined cardiovascular disease' (myocardial infarction and stroke), 17, 18 while an unrelated genetic variant of the gene coding for the a subunit was associated with a higher risk of hypertension. 33 Finally, estradiol has also been shown to activate BK channels, probably through the binding to the b 1 subunit, 34 an effect that may contribute to gender differences in basal vascular tone and myogenic responses. Similar results have been obtained using xenoestrogens and cholanederived steroids. 35, 36 Altogether, this evidence provides considerable incentive for the development of new antihypertensive therapeutic agents that target the vascular BKab 1 channel. A variety of small synthetic molecules (for example, NS1619) and natural compounds (such as dehydrosoyasaponin-I (DHS-I)) have been identified as BK channel openers. However, little is known about their site(s) of interaction, and most have serious safety and/or efficacy problems for clinical use (reviewed in 37 ). NS1619 and other benzoimidazolones have been extensively used in the research of BK channel functions, but it has become apparent that their therapeutic usefulness is rather limited by low potency and inadequate selectivity. 37 Likewise, while DHS-I is an effective activator of the vascular BKab 1 channel when applied on the channel intracellular side, its medical application is limited by poor membrane permeability. 37 Tungstate reduces blood pressure in experimental animal models of both hypertension 21, 22 and metabolic syndrome. 23 This antihypertensive effect of tungstate may be achieved by inhibition of endothelial xanthine oxidase, 21 and we now report a dual action of tungstate on -knockout mouse arteries pre-contracted with endothelin-1. This vasodilatory action was not related to the reported tungstate-induced inhibition of the endothelial xanthine oxidase, 21 because it was not replicated by allopurinol. It was reported before that sodium tungstate (0.1 mM) pre-treatment for 10 min of rat mesenteric branch arteries was without effect on the Ca 2+ -induced relaxation over the phenylephrine-induced contraction. 40 Differences regarding the experimental protocol and/or the biological material under study might account for the distinct results obtained, when compared with our work. Regarding the possible sites for tungstate interaction in the BK channel, the two cytoplasmic regions of the a subunit (belonging to the VSD and the RCK1 domain) that have been shown by mutagenesis to impact channel activation induced by either Mg 2+ (present study and 8 ) or tungstate (present study) contain a DK/KD motif within or next to the mutated residue (Supplementary material online, Figure S3 and Table S2 ). For instance, in site 1, located in the cytoplasmic region between S0 and S1, the mutated D99 is part of a KD motif ( Tungstate has a low toxicity profile in animals and humans, and the results of the first proof-of-concept clinical trial (TROTA-1) on the efficacy of sodium tungstate in grade I and II human obesity have already been reported. 41 Contrary to the results obtained in rodent models of obesity, the data obtained from the clinical trial did not sustain sodium tungstate as a pharmacological tool in the treatment of human obesity. The subjects included in the trial, besides being moderately obese, were non-diabetic and mostly normolipidaemic and normotensive. The results obtained did not reveal significant changes in glucose/lipid metabolism or in blood pressure after the active treatment with tungstate. 41 The reasons for the discrepancy in the actions of tungstate between rodents and humans remain to be elucidated. The lack of efficacy of tungstate in humans may be attributed to an inadequate duration of the active treatment, to the dose of sodium tungstate being too low, or to alterations in the expression of enzymes involved in the regulation of energy homeostasis. 41 In one parameter, however, there was agreement between the laboratory animals and humans; tungstate does not affect blood pressure in normotensive subjects. 21, 41 This observation, together with the fact that the vasodilatory concentration of tungstate used in the present study (100 mM) was only slightly higher than the tungstate levels measured in the plasma of both treated rodent models and humans ( 5-20 mM), 19,41 also encourages future studies in order to investigate the molecular mechanisms of action of tungstate further and to test the utility of tungstate as an antihypertensive agent in humans, either by itself or in combination with other therapeutic tools.
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